Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)
In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
In silico designing of targeted protein degraders
Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Targeting SWI/SNF ATPases in enhancer-addicted human cancers
Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor SITC, Nov 2022
